Korkusuz, F.Korkusuz, P.Ekşioğlu, F.Gürsel, I.Hasirci, V.2020-06-252020-06-252001closedAccess0021-9304https://doi.org/10.1002/1097-4636(200105)55:2<217https://hdl.handle.net/20.500.12587/2926KORKUSUZ, FEZA/0000-0001-9486-3541; Gursel, Ihsan/0000-0003-3761-1166; KORKUSUZ, PETEK/0000-0002-7553-3915In this study, the major goal was to evaluate in vitro and in vivo findings by macroscopy, radiology, and histology to determine the effectiveness of therapy of experimental implant-related osteomyelitis with antibiotic carrier rods constructed of microbial polyesters. The polymers used were poly(3-hydroxybutyrate-co-4-hydroxyvalerate) [P(3HB-co-4-HB)] and poly(3-hydroxybutyrate-co-3-hydroxy-valerate) [P(3-HB-co-3-HV)]. Both the Sulperazone(R) and the Duocid(R)-P(3-HB-co-4-HB) rods with a drug to polymer ratio of 1:1 (w/w) were effective in treating the bone infection that was experimentally initiated by inoculation of a hemolytic strain of Staphylococcus aureus (coagulase positive; phage type 52/52b) together with metal implants into the medullary area of rabbit tibia. Macroscopical data revealed that the effectiveness of therapy was apparent at week 6 for all categories tested. Radiological findings with Duocid(R)- and Sulperazone(R)-loaded P(3-HB-co-4-HB) rods improved significantly when judged by changes in periosteal elevation, widening of bone shaft, new bone formation, and soft-tissue deformation after 6 weeks of implantation. Histologically the signs of infection were found to subside by weeks 3 and 6. inflammatory cells were replaced with bone-forming cells upon treatment with Sulperazone(R)-P(3-HB-co-4-HB) and Duocid(R)-P(3-HB-co-4-HB). Osteoblastic activity was prominent. Intramedullary inflammation, although still present, started to be replaced by fibrous or bony tissue. Histological findings presented the subsidence of infection. In summary, the antibiotic-loaded biopolymeric rods appeared to have potential as a new controlled-release system for the treatment of implant related osteomyelitis and chronic osteomyelitis. (C) 2001 John Wiley & Sons, Inc.eninfo:eu-repo/semantics/closedAccessosteomyelitissustained releaselocal antiinfective agentsbiodegradable delivery systemspolymerspoly(hydroxybutyrate-co-hydroxyvalerate)In vivo response to biodegradable controlled antibiotic release systemsArticle55221722810.1002/1097-4636(200105)55:2<2172-s2.0-003509011211255173N/AWOS:000167221200009Q1